CASE REPORT

A rare case of severe systemic life-threatening botulism caused by a local botulinum toxin-A injection

Xiaoxi Tian, MD, a Lin Gao, MD, b Guoqiang Fu, MD, a Cuicui Zhang, MD, a Qianfeng He, MD, a Ni Wei, MD, a Tan Huang, MD, a and Lihong Li, MD a

Xi’an, China

Key words: botulinum toxin; complications; cosmetic therapy.

INTRODUCTION

Botulinum toxin (BTX) is produced by a gram-positive anaerobic bacterium called Clostridium botulinum. BTX is among the deadliest natural substances known to humans with an estimated lethal dose of 1 ng/kg.1,2 There are 7 types of this neurotoxin- BTX-A, -B, -C1, -C2, -D, -E and -F. Human botulism is caused mainly by types A, B, E, and rarely F.3 BTX can cleave the presynaptic protein snap-25, inhibit acetylcholine release, and block the neuromuscular junction.4,5 BTX was first used in humans to treat strabismus in 1973, and later its applications were extended to many other conditions such as neurogenic detrusor overactivity, chronic migraine, muscle spasticity, axillary hyperhidrosis, and blepharospasm.6 Furthermore, BTX has been approved in more than 50 countries and has become the first-choice nonsurgical procedure for facial rejuvenation since 2000.7 However, many adverse events have been described such as dry mouth, pain at injection site, fatigue, headache, neck pain, weakness, and eye problems including double vision, blurred vision, decreased eye sight, eyelid ptosis, eyelid swelling, brow ptosis, and dry eyes. More serious adverse events such as ashenia, excessive weakness, dysphagia, dysphonia, dysarthria, urinary incontinence, and aspiration pneumonia have been documented.8-10 Here, we report a rare case of a patient who had systemic life-threatening complications after self-administration of an overdose of BTX-A which was obtained from an underground market.

CASE REPORT

A 25-year-old woman who just graduated from a nursing school was admitted into our emergency care unit on April 11, 2019. She presented with sudden dizziness, severe headache, fainting, and blurred vision for 7 days and a recent development of dysphagia for 1 day. She described that she purchased 1 bottle labeled as “Thigh Slimming Injection” from a local cosmetic spa store and administered it into her left lower extremity at multiple sites in a single session 11 days prior. There was no essential product information on the label of the bottle, including brand name, ingredients, expiration date, or manufacturer. Her symptoms immediately after injection included edema and muscle tenderness in her left lower extremity, but the patient disregarded these initial symptoms. Then, 5 days after injection, she reported...
feeling fatigue, general weakness, shortness of breath, dizziness, diplopia, and visual disturbance. She went to the first local hospital for regular checks on days 5 and 7 but was told that she was normal on examinations. At a second hospital, she was given a Chinese traditional cupping therapy on days 9 and 10. She had no improvement of her signs or symptoms. Subsequently, she became very weak, was unable to walk, and had dysphagia and a choking sensation to water. At our hospital, she was admitted to the emergency department on day 11 after the injection.

The patient had an unremarkable medical history and was in overall good health prior to this incident. Upon admission, a series of laboratory examinations were performed (Table I). The abnormal laboratory tests were as follows. (1) The complete blood count showed higher levels of white blood cells (11.3; reference [ref], 3.2-9.7 x 10^9/L) and monocytes (0.71; ref, 0-0.45 x 10^9/L), and mean corpuscular hemoglobin (34.4; ref, 26.9-33 pg). (2) Coagulation assays showed elevated prothrombin time (13.2; ref, 9.8-12.1 seconds) and decreased percentage of plasma thromboplastin antecedent (69.5; ref, 80%-120%). (3) Metabolic profiles showed increased levels of total protein (91.0; ref, 63-82 g/L), albumin (52.5; ref, 35-50 g/L), globulins (38.5; ref, 20-32 g/L), total bilirubin (58.76; ref, 3-22 μmol/L), conjugated bilirubin (6.91; ref, 0-5.0 μmol/L), and unconjugated bilirubin (51.85; ref, 0-19, μmol/L). Other laboratory findings appeared to be normal (Table I). The results from electrocardiography and head, neck, and chest computed tomography scans were normal.

Electromyogram (EMG) recordings on various motor and sensory nerves were carried out. Amplitudes of compound muscle action potentials (CMAP) for motor branches of musculocutaneous (biceps brachii-Erb point) and axillary (deltoid-Erb point) nerves were below the normal ranges (Table I). The amplitudes of CMAP for bilateral ulnar motor nerves (wrist-below elbow) were at the low threshold levels of the normal ranges (Table I). The tests on other muscles and nerves appeared to be normal (Table I).

In addition, a serum sample was sent to Shaanxi Provincial Center for Disease Control and Prevention (SXCD) for a toxin detection. It was found to be positive for BTX-A and negative for BTX-B using a colloidal gold-based immunochromatographic assay. Severe botulism caused by an overdose of BTX-A was the diagnosis. The incident was reported to SXCD.

The patient was treated by intramuscular injection of 10,000 U of a botulinum antitoxin (HBAT) into the ventrogluteal muscle of the hip daily for 17 days. The patient felt an immediate alleviation of dysphagia.

### Table 1. Patient's laboratory values on admission

| Testing category                  | Results       | Reference | Unit   |
|-----------------------------------|---------------|-----------|--------|
| Complete blood count              |               |           |        |
| White blood cells                 | 11.3 †        | 3.2-9.7   | x10^9/L|
| Lymphocytes                       | 3.50          | 0.64-3.88 | x10^9/L|
| Monocytes                         | 0.71†         | 0-0.45    | x10^9/L|
| Neutrophils                       | 7.03          | 1.6-7.3   | x10^9/L|
| Eosinophils                       | 0.05          | 0-0.45    | x10^9/L|
| Basophils                         | 0.02          | 0-0.2     | x10^9/L|
| Platelets                         | 256           | 100-300   | x10^9/L|
| Platelet distribution width       | 12.3          | 15.5-18.1 | %      |
| Red blood cells                   | 4.54          | 3.5-5     | x10^9/L|
| Mean corpuscular hemoglobin      | 34.4†         | 26.9-33   | pg     |
| Coagulation tests                 |               |           |        |
| Prothrombin time                  | 13.2†         | 9.8-12.1  | s      |
| Plasma thromboplastin antecedent  | 69.5†         | 80-120    | %      |
| Activated partial thromboplastin  | 27.2          | 21.1-36.5 | s      |
| Fibrinogen                        | 2.69          | 1.8-3.5   | g/L     |
| Thrombin time                     | 17.4          | 14-21     | s      |
| Fibrinogen degradation products   | 2.20          | 0-5       | μg/mL   |
| D-dimer                           | 0.64          | 0-1       | μg/mL   |
| Blood gas analysis                |               |           |        |
| PH                                | 7.390         | 7.35-7.45 |        |
| PaCO2                             | 30.8          | 38-42     | mmHg    |
| PaO2                              | 84.7          | 80-100    | mmHg    |
| Cerebrospinal fluid analysis      |               |           |        |
| Chloride                          | 124.3         | 120-132   | mmol/L  |
| Glucose                           | 2.56          | 2-2.39    | mmol/L  |
| Protein                           | 447.64        | 120-600   | mg/L    |
| Metabolic markers                 |               |           |        |
| Creatine kinase                   | 0.63          | 0-2.37    | ng/mL   |
| Creatine kinase myoccardial band  |               |           |        |
| Troponin I (cTnl)                 | <0.012        | 0-0.04    | ng/mL   |
| Myoglobin                         | 58.33         | 0-61.5    | mg/L    |
| Total protein                     | 91.0†         | 63-82     | g/L     |
| Albumin                           | 52.5†         | 35-50     | g/L     |
| Globulins                         | 38.5†         | 20-32     | g/L     |
| ALB/GLO                           | 1.4†          | 1.5-2.5   | %       |
| Total bilirubin                   | 58.76†        | 3-22      | μmol/L  |
| Conjugated bilirubin              | 6.91†         | 0-5.0     | μmol/L  |
| Unconjugated bilirubin            | 51.85†        | 0-19      | μmol/L  |
| Alanine aminotransferase          | 28            | 15-46     | U/L     |
| Alanine transaminase              | 28            | 11-66     | U/L     |
| Gamma-glutamyl transferase        | 24            | 12-43     | U/L     |
| Alkaline phosphatase              | 85            | 38-126    | U/L     |
| Glucose                           | 6.02          | 4.1-5.9   | mmol/L  |
| Blood urea nitrogen               | 6.36          | 3.2-7.1   | mmol/L  |
| Creatinine                        | 72.2          | 28-110    | μmol/L  |
| Uric acid                         | 391.8         | 208-506   | μmol/L  |
| Procalditomin                     | <0.20         | <0.5      | ng/mL   |
| Chloride                          | 104.9         | 98-107    | mmol/L  |
| Calcium                           | 2.47          | 2.1-2.55  | mmol/L  |
| Potassium                         | 3.63          | 3-5.1     | mmol/L  |
| Sodium                            | 143.7         | 137-145   | mmol/L  |

ALB/GLO, Albumin to globulin ratio.
3 hours after the first injection, and showed a progressive and full recovery from dysphagia 2 days later. However, the symptoms such as weakness, dizziness, diplopia, and blurred vision remained. After 3 days of treatment, the patient could walk and had a clear vision within 1 meter. On day 10, the patient felt no dizziness but still had weakness, diplopia, and blurred vision at farther distances. On day 14, the patient’s diplopia improved, and her vision was clear to 3 meters. On day 17, the patient had full resolution of the diplopia and blurred vision, but she still felt weak. The patient was discharged the next day. The patient was fully recovered at her 1-week follow-up. The patient did not show any long-term adverse events at her evaluation 6 months after hospitalization.

**DISCUSSION**

In the past decades, BTX has emerged as the most popular minimally invasive procedure for facial rejuvenation. The safety profile for BTX applications has always been a major concern in cosmetic clinics, although the adverse events caused by BTX are generally considered reversible, short-term, localized, and not life threatening. In 2009, the US Food and Drug Administration issued a safety warning that said the toxin “may spread from the area of injection to produce symptoms of botulism.” Adverse effects such as muscle weakness, dizziness, and difficulty breathing can occur hours or weeks after an injection, depending on the volume and dosage (the number of units) of injected BTX. Recent evidence shows that BTX can spread to distant sites either via the neuroaxonal or hematogenous transport, which may account for the systemic complications observed in our patient. Affected individuals may feel fatigue, headache, and dizziness at early stage but generally have normal basic laboratory examinations and imaging scans, which makes early diagnosis difficult. Our patient’s botulism was misdiagnosed twice at a local hospital; therefore, the early diagnosis window was missed to prevent the development of systemic complications. Based on the history of patient’s administration of unknown substances, we performed neurophysiologic tests and blood tests. A typical CMAP amplitude decrease was found in EMG recordings in some types of motor nerves from the patient such as musculocutaneous, axillary, and ulnar branches. Furthermore, the SXCDC confirmed the presence of BTX-A in the patient’s serum. Therefore, the combination of these tests confirmed the diagnosis of systemic botulism.

A few good lessons came from this case. First, both practitioners and patients should have full knowledge of and be aware of the dangerous side effects of using BTX, including the possible systemic complications, although rare. Educating patients is of particular importance. The injection of BTX should be performed by well-trained practitioners using a standard protocol. The volume and dosage must be very tightly controlled to avoid any severe adverse outcomes. Second, the cosmetic industry is largely unregulated in China, including both the black-market products and the places in which cosmeticians practice. For example, many practitioners employed by cosmetic private clinics, spas, or salons have not received standard medical training nor have they been certified. Regardless, they have been regularly performing injectable procedures such as BTX and dermal fillers since release of these substances to the market in China. Our patient bought a bottle labeled as Thigh Slimming Injection from a local cosmetic spa store without any prescription. This cosmetic store was not authorized to provide that patient with BTX. Thigh Slimming Injection is not a Chinese Food and Drug Administration–approved

| Nerves                          | Amplitude (mV) | Reference (mV) |
|--------------------------------|----------------|----------------|
| Ulnar, left                     |                |                |
| Wrist-below elbow               | 4.7*           | ≥ 5            |
| Wrist-above elbow               | 6.4            | ≥ 5            |
| Ulnar, right                    |                |                |
| Wrist-below elbow               | 5.0            | ≥ 5            |
| Wrist-above elbow               | 6.7            | ≥ 5            |
| Median, wrist-elbow             |                |                |
| Left                           | 6.6            | ≥ 5            |
| Right                          | 6.6            | ≥ 5            |
| Radial, above elbow-spiral groove |            |                |
| Left                           | 4.4            | ≥ 3            |
| Right                          | 4.5            | ≥ 3            |
| Musculocutaneous, biceps brachii-Erb point |          |                |
| Left                           | 3.9*           | ≥ 5            |
| Right                          | 3.9*           | ≥ 5            |
| Peroneal, fibula-popliteal fossa |            |                |
| Left                           | 10.5           | ≥ 3            |
| Right                          | 11.5           | ≥ 3            |
| Axillary, deltoid-Erb point     |                |                |
| Left                           | 3.2*           | ≥ 5            |
| Right                          | 3.0*           | ≥ 5            |

*These are the abnormally low values, which caused concern for systemic botulism.
product and was sold in the underground market. The policymakers need to close these loopholes and implement appropriate measures to regulate both the injectors and the sales of illegal products with the entire industry both nationally and locally.

REFERENCES
1. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059-1070.
2. Sesardic D, Jones RG, Leung T, Alsop T, Tierney R. Detection of antibodies against botulinum toxins. Mov Disord. 2004; 19(Suppl 8):S85-S91.
3. Lindstrom M, Korkeala H. Laboratory diagnostics of botulism. Clin Microbiol Rev. 2006;19:298-314.
4. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200-3205.
5. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993; 365:160-163.
6. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the “sausage poison”. Neurology. 1999;53:1850-1853.
7. Hotta TA. ASAPS (American Society of Aesthetic Plastic Surgery)–2013 Annual Statistics. Plast Surg Nurs. 2014;34: 47-48.
8. Sorensen EP, Urman C. Cosmetic complications: rare and serious events following botulinum toxin and soft tissue filler administration. J Drugs Dermatol. 2015;14:486-491.
9. Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95:65-69.
10. Allergan. Highlights for prescribing information for Botox cosmetic 2019. Available at: https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/20190620-BOTOX-100-and-200-Units-v3-0USPI1145-v2-0MG1145.pdf. Accessed August 11, 2020.
11. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28:1775-1783.